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INTRODUCTION
Nontuberculous mycobacteria (NTM) are important envi-
ronmental pathogens that cause a broad spectrum of diseases
(1). NTM infections have been reported worldwide with vary-
ing frequencies (2-4), while the isolation rates and the inci-
dences of diseases caused by NTM are increasing in Korea
(5-8). In a nationwide survey from 1981 to 1994, the inci-
dences of Mycobacterium avium-intracellulare complex (MAC),
M. fortuitum, and M. chelonae were 65.2%, 12.7%, and 9.5%,
respectively, among all NTM infections (5). And also, another
report confirmed that MAC isolates were the most frequent
in clinical specimens in mid-1990s, followed by M. abscessus
and M. fortuitum (8). Rapidly growing mycobacteria (RGM)
such as M. fortuitum, M. abscessus, and M. chelonae cause several
forms of clinical diseases of varying severity, most common-
ly skin and soft tissue infections, but they also cause skele-
tal, pulmonary, and disseminated diseases (4, 9). In particu-
lar, MAC, M. fortuitum, and M. abscessus have been reported
to be associated with clinical pulmonary diseases (6, 10-12).
NTM cause infections more commonly in the presence of
predisposing factors and/or underlying diseases (4, 13) and
are often considered contaminants. Because these organisms
are notably resistant to the antimicrobial agents commonly
used to treat tuberculosis (4, 14), susceptibility testing is
indicated for any RGM that is considered clinically signifi-
cant (e.g., isolates from blood, tissue, skin, and soft tissue
lesions) (14, 15). The statement on the diagnosis and treat-
ment of diseases caused by NTM issued by the American
Thoracic Society suggests that a minimum of seven drugs
(amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycy-
cline, imipenem, and a sulfonamide) should be tested against
clinically significant RGM (14), and the Clinical and Labo-
ratory Standards Institute (CLSI) recommends that the stan-
dard broth microdilution method be used for the suscepti-
bility testing of M. fortuitum, M. chelonae, and M. abscessus (15).
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Evaluation of the Broth Microdilution Method Using 2,3-Diphenyl-5-
thienyl-(2)-tetrazolium Chloride for Rapidly Growing Mycobacteria
Susceptibility Testing
As the incidence of nontuberculous mycobacterial infection has been increasing
recently in Korea, the importance of drug susceptibility test for clinical isolates of
mycobacteria has become larger. In this study we determined the antimicrobial
susceptibility patterns of clinical isolates of M. fortuitum and M. abscessus in Korea,
and evaluated the efficacy of a modified broth microdilution method using 2,3-di-
phenyl-5-thienyl-(2)-tetrazolium chloride (STC), in terms of its ability to provide
accurate and easy-to-read minimal inhibitory concentration (MIC) endpoints for the
susceptibility testing of rapidly growing mycobacteria. Most isolates of M. fortuitum
and M. abscessus in Korea are susceptible or intermediately susceptible to amikacin,
cefoxitin, ciprofloxacin, and clarithromycin. Many isolates of M. fortuitum are sus-
ceptible to doxycycline, sulfamethoxazole, and imipenem, while many M. absces-
sus isolates are resistant to these drugs. In the present study, the modified broth
microdilution method using STC was found to be reliable, easy to read, and inex-
pensive for M. fortuitum and M. abscessus susceptibility testing. The modified col-
orimetric MIC testing method using STC was proven to be a useful surrogate for
RGM antibiotic susceptibility testing. 
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Although the broth microdilution procedure is widely used
for the susceptibility testing of several antibiotics on a large
number of bacterial isolates, several difficulties concerning
MIC interpretation for RGM interfere with the susceptibil-
ity testing of these isolates (16, 17). Moreover, because the
incidence of NTM infection is not high, only a few reference
centers are able to offer the susceptibility testing of clinically
significant strains as a service. Actually no comparative data
on the susceptibility testing of these organisms is available
in Korea. Thus, a more convenient and easy-to-interpret
method of susceptibility testing seems important. As a mod-
ification of the CLSI standard method, the colorimetric or
spectrophotometric MIC endpoint determination could be
applied using color indicators. 2,3-diphenyl-5-thienyl-(2)-
tetrazolium chloride (STC) (TCI, Tokyo, Japan) is an oxida-
tion-reduction indicator that changes from colorless to red
as the organisms grow, and has been applied in mycobacteri-
al or fungal susceptibility testing (18-20). The purpose of
this study was to determine the antimicrobial susceptibility
patterns of clinical isolates of M. fortuitum and M. abscessus in
Korea, and to evaluate the broth microdilution method using
STC in terms of its ability to provide accurate and easy-to-read
minimum inhibitory concentration (MIC) endpoint results
for the antimycobacterial susceptibility testing of RGM.
MATERIALS AND METHODS
Antimicrobial drugs and reagents 
The antimicrobial agents and their concentrations (in serial
2-fold dilutions) tested against RGM for MIC determinations
were amikacin (0.5-64  g/mL), cefoxitin (1-128  g/mL),
ciprofloxacin (0.03-4  g/mL), clarithromycin (0.06-8  g/
mL), doxycycline (0.125-16  g/mL), imipenem (0.25-32  g/
mL), and sulfamethoxazole (1-128  g/mL). The drugs were
purchased from Sigma Chemical (St. Louis, MO, U.S.A.),
except clarithromycin (Abbott Laboratories, North Chica-
go, IL, U.S.A.) and imipenem (Choongwae, Seoul, Korea).
Antibiotic stock solutions were made by dissolving powders
in distilled water, methanol or phosphate buffer, and were
divided into 1 mL aliquots and frozen at -70℃until required,
except imipenem, which was used immediately after prepa-
ration. On the day of testing, antibiotic stock solutions were
thawed and diluted in cation-supplemented Mueller-Hin-
ton broth (Becton Dickinson, Sparks, MD, U.S.A.). 
STC was dissolved in distilled water at 5 g/L at room tem-
perature. This solution was filtered through a 0.20  m fil-
ter (Corning, Corning, NY, U.S.A.) and then stored at -70℃
until needed. The solubilizing agent used to dissolve reduced
tetrazolium (STC) precipitates was prepared by dissolving
20% (w/v) sodium dodecyl sulfate (Bio-Rad, Hercules, CA,
U.S.A.) in 50% (v/v) N,N-dimethylformamide (Sigma Chem-
ical), and was stored unfiltered at room temperature.
Bacterial strains and cultures 
Fifty-five M. fortuitum and 48 M. abscessus strains isolated
from clinical specimens were collected from Ulsan Univer-
sity Hospital (UUH) and Korean Institute of Tuberculosis
(KIT). Species identification was carried by high-performance
liquid chromatography (strains isolated in UUH) or by poly-
merase chain reaction (PCR)-restriction fragment length poly-
morphism analysis of the rpoB gene (strains provided by KIT)
(14, 21-23). Strains were maintained on Lowenstein-Jensen
media slants at room temperature until required for testing.
To prepare the inoculum suspension for broth microdilution
tests, strains were subcultured in cation-supplemented Mue-
ller-Hinton broth and incubated at 35℃ for 2 to 4 days to
a turbidity of ≥0.5 McFarland standard by visual examina-
tion.
Staphylococcus aureus ATCC 29213 strain was tested at the
beginning of each study as a quality control, as recommend-
ed by CLSI (15). Quality control was considered acceptable
if MIC results were within tentative quality control ranges
of MICs as recommended by CLSI (15, 16). 
CLSI broth microdilution method
Antimicrobial susceptibility testing was performed by the
broth microdilution method using cation-supplemented
Mueller-Hinton broth, according to CLSI guidelines (CLSI
broth microdilution method) (15, 17). Inoculum suspensions
were prepared by diluting broth culture supernatant in ster-
ile distilled water to a density of 0.5 McFarland standards
using a nephelometer (BioMerieux Vitek Inc, Hazelwood,
MO, U.S.A.). The final concentrations of mycobacteria rang-
ed from 1×105 to 5×105 CFU/mL. Suspensions were mix-
ed well on a vortex mixer and dispensed using a multichan-
nel pipette into each well of a 96-well microplate (SPL, Hwa-
sung, Korea) containing broth medium and antimicrobial
drugs at serial concentrations. Final inoculums were between
1×104 and 5×104 CFU per well in a volume of 0.2 mL.
Inoculated plates were covered and incubated at 35℃. A
5% sheep blood agar plate was also inoculated with a loop-
ful of the final inoculum suspension to check for purity. If
quality control results were not acceptable, or contamina-
tion or mixed culture was suspected, all data were discard-
ed. For M. fortuitum, growth endpoints were read visually
after 3 days of incubation. For M. abscessus, trays were re-incu-
bated and read daily for up to 5 days until bacterial growth
in the control well was good enough for reading. MIC val-
ues were defined as the lowest concentration of drug that
inhibited visible growth, except for sulfamethoxazole, for
which the concentration that inhibited growth by 80 to 90%
versus a control well with no drug was used, according to
the CLSI guideline (15). MIC readings for imipenem were
taken at 72 hr for all strains. All measurements were per-
formed in duplicate for each strain. To assess potential impact
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on patient management, MIC results were interpreted based
on the RGM interpretive category using the breakpoints
suggested by CLSI. 
STC broth microdilution 
The colorimetric broth microdilution method with STC
(STC broth microdilution) was identical to the broth micro-
dilution method described by CLSI in terms of reagents, me-
dium preparation, inoculum, drug concentrations, and incu-
bation time, with one exception, namely, that STC was added
to the cation-supplemented Mueller-Hinton broth with anti-
microbial agents to a final concentration of 50  g/mL. After
bacterial growth, dark-colored precipitates were observed in
wells containing STC-added media. After adding a solubi-
lizing agent and incubating for 2 hr, wells showing microbial
growth were pink-colored. Color changes corresponding to
microbial growth and each strain-drug-MIC endpoint were
recorded visually at 72 hr. The broth microdilution method
using STC was checked by comparing growth in each test
well with that in control wells. Wells containing the lowest
drug concentration that showed a prominent reduction in
color change were considered MICs. For sulfamethoxazole,
wells colored light pink were considered to reflect MIC end-
points, and these showed growth inhibition of 80 to 90%
versus control wells.
Comparison of the results between the CLSI and STC
methods
Levels of agreement between the two broth microdilution
methods with or without STC were calculated for each strain-
drug-MIC endpoint and were expressed as percentages at the
same MIC or as MICs within one or two 2-fold dilutions. The
interpretive category results were also analyzed by compar-
ing the results of two methods so as to determine whether
the performance was acceptable according to the CLSI guide-
line (24). The discrepancy cases were classified to very major
error (resistant by CLSI method but susceptible by STC
method), major error (susceptible by CLSI method, resistant
by STC method), and minor error (intermediate result was
obtained by one method but not by the other). The rates of
agreement were calculated as the percentage of isolates with
MICs in the range of two 2-fold dilution.
RESULTS
MICs of the CLSI broth microdilution method
The MIC results determined by using the CLSI broth mic-
rodilution method are shown in Table 1 and 2 for seven drugs
and a number of strains. M. fortuitum strains achieved maxi-
mum growth at 72 hr for the broth microdilution test meth-
Agents
No. of strains distributed at the MIC ( g/mL)
0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
Table 1. Minimal inhibitory concentrations (MICs) of 7 antimicrobial agents for 55 strains of M. fortuitum by CLSI broth microdilution
*High off-scale MICs were converted to the next-highest concentration; 
� Low off-scale MICs were converted to the next-lowest concentration.
Solid and shadowed boxes indicate susceptible and resistant categories of interpretive criteria to each antibacterial agent, respectively.
Agents
No. of strains distributed at the MIC ( g/mL)
0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
Table 2. Minimal inhibitory concentrations (MICs) of 7 antimicrobial agents for 48 strains of M. abscessus by CLSI broth microdilution 
*High off-scale MICs were converted to the next-highest concentration; 
� Low off-scale MICs were converted to the next-lowest concentration.
Solid and shadowed boxes indicate susceptible and resistant categories of interpretive criteria to each antibacterial agent, respectively.
Amikacin 51* 0 2 1 1 0 0 0 0 0
�
Cefoxitin 0* 0 0 3 8 19 20 5 0 0
�
Ciprofloxacin 29* 0 19 1 1 2 0 3 0 0
�
Clarithromycin 15* 0 5 13 4 4 5 5 2 2
�
Doxycycline 21* 0 1 1 5 6 9 3 3 6
�
Imipenem 7* 0 12 18 13 4 1 0 0 0
�
Sulfamethoxazole 4* 0 10 16 5 6 6 5 1 2
�
Amikacin 5* 0 17 19 2 2 0 1 0 2
�
Cefoxitin 0* 0 0 0 0 5 34 6 3 0
�
Ciprofloxacin 2* 0 0 1 3 2 13 20 4 3
�
Clarithromycin 19* 0 8 6 4 2 1 6 0 2
�
Doxycycline 1* 0 1 2 0 5 6 3 2 28
�
Imipenem 0* 0 0 1 2 1 27 12 4 1
�
Sulfamethoxazole 0* 0 0 2 0 1 3 13 8 21
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ods with or without STC. For most strains of M. abscessus,
maximum growth in broth also occurred at 72 hr, but some
strains (10 of 48) showed maximum growth at 96 hr. M. for-
tuitum showed consistently low MICs to amikacin and cipro-
floxacin, and a wide range of MICs to the other five drugs.
Isolates of M. abscessus showed a wide range of MICs to all
drugs. MIC results converted to interpretive categories using
the breakpoints suggested are shown in Table 3. For M. fortu-
itum, all strains were fully susceptible to amikacin, and most
strains were susceptible or intermediately susceptible to cefox-
itin, ciprofloxacin, clarithromycin, and imipenem. For M. ab-
scessus, most strains were susceptible or intermediately suscep-
tible to amikacin, cefoxitin, ciprofloxacin, and clarithromycin.
Doxycycline, imipenem, and sulfamethoxazole showed lower
MICs for M. fortuitum isolates and higher MICs for M. abscessus.
Agreement between the CLSI and STC broth microdilution
methods
Comparisons of the growth of a strain of M. fortuitum on the
broth media are shown in Fig. 1, 2 in 96-well microplates,
which demonstrate an obvious advantage of the STC broth
microdilution method. The MICs of 7 antimicrobial agents
obtained using the STC broth microdilution method corre-
lated well with those obtained using the CLSI broth dilu-
tion method (Table 4). Agreements by interpretative cate-
gory for the two methods are presented in Table 5. In 85 of
103 bacterial strains (44 of 55 M. fortuitum strains and 41 of
48 M. abscessus strains), the MICs of all 7 antimicrobial agents
tested were within two 2-fold dilutions of those obtained by
Species 
(No.of 
strains)
M. fortuitum (55)
S (%) I (%) R (%) Agents
M. abscessus (48)
S (%) I (%) R (%)
Amikacin 55 (100) 0 0 45 (94) 1 (2) 2 (4)
Cefoxitin 30 (55) 25 (45) 0 5 (11) 40 (83) 3 (6)
Ciprofloxacin 52 (95) 3 (5) 0 21 (44) 20 (42) 7 (14)
Clarithromycin 46 (84) 5 (9) 4 (7) 40 (83) 6 (13) 2 (4)
Doxycycline 28 (51) 18 (33) 9 (16) 4 (8) 14 (29) 30 (63)
Imipenem 54 (98) 1 (2) 0 4 (8) 27 (56) 17 (36)
Sulfamethoxazole 47 (85) - 8 (15) 6 (12) - 42 (88)
Table 3. Susceptibility results of rapidly growing nontuberculous
mycobacteria by CLSI broth microdilution
Fig. 1. Growth of M. fortuitum in Mueller-Hinton broth. (A) Media without STC, and (B) STC-containing media.
A B
Fig. 2. Growth of M. fortuitum in Mueller-Hinton broth. (A) Media
without STC, (B) solubilizing agent added in STC-containing media,
and (C) STC-contatining media, in which dark precipitates were
observed before solubilization.
Species 
M. fortuitum (%) Agents M. abscessus (%)
Amikacin 54/55 (98.2) 48/48 (100)
Cefoxitin 55/55 (100) 48/48 (100)
Ciprofloxacin 55/55 (100) 47/48 (97.9)
Clarithromycin 54/55 (98.2) 46/48 (95.8)
Doxycycline 53/55 (96.4) 47/48 (97.9)
Imipenem 55/55 (100) 47/48 (97.9)
Sulfamethoxazole 48/55 (87.3) 46/48 (95.8)
Table 4. Agreement by MICs of antimycobacterial agents am-
ong CLSI and STC broth microdilution methods
A
B
C
MIC, minimal inhibitory concentration.
S, susceptible; I, intermediate; R, resistant.788 S.M. Lee, J.M. Kim, J. Jeong, et al.
the CLSI method. For each of these agents, the overall agree-
ment at±2 log2 dilution ranged from 95.8% to 100.0%
between the two methods except for the result of M. fortui-
tum to sulfamethoxazole (48 of 55 strains, 87.3%). Agree-
ments of CLSI and STC broth microdilution methods by
interpretative category results to amikacin, cefoxitin, clary-
thromycin, and doxycycline were excellent without major
errors. Because the MIC results of M. fortuitum for cefoxitin
were clustered at 16-32  g/mL, the breakpoint of the sus-
ceptible and intermediate categories, 15 minor errors were
identified. Similarly, the MICs of M. abscessus for ciprofloxacin
were clustered at 1-2  g/mL, which corresponded to 19 minor
and one very major errors. In total 721 organism-antimicro-
bial agent combinations were analyzed, 9 of 18 MIC dis-
crepancies (out of two 2-fold dilution), 5 of 6 major errors,
and 8 of 9 very major errors originated uniquely from sul-
famethoxazole test results (Table 5).
DISCUSSION
In general, the MIC results of M. fortuitum and M. abscessus
isolates to antimicrobial drugs in this study were similar to
those previously reported by other investigators (1, 14, 25-
28). Most of the tested strains of M. fortuitum were found to
be susceptible or intermediately susceptible to amikacin (100
%), cefoxitin (100%), ciprofloxacin (100%), clarithromycin
(93%), doxycycline (84%), and imipenem (100%). In addi-
tion, most strains of M. abscessus were susceptible or inter-
mediately susceptible to amikacin (96%), cefoxitin (94%),
and clarithromycin (96%). Ciprofloxacin and imipenem
results for M. abscessus showed more susceptible than the
results by other researchers (1, 14, 26).
It is known that results for RGM susceptibility to imipen-
em show a lack of reproducibility, so in a routine laboratory
setting, it is recommended to repeat the test if the MIC for
M. fortuitum is >8  g/mL, and to report the MIC result with
the comment ‘MIC greater than expected for this species’ if
the repeat result is >8  g/mL (15). In this study, no strain
was found to have an MIC higher than 8  g/mL. The MIC
results of M. abscessus to imipenem were mainly clustered in
the range 8-16  g/mL, but the CLSI guideline suggests that
MIC results should not be reported because imipenem MICs
for this species tend not to be reproducible, which results in
major susceptibility category changes (15, 28).
Susceptibility testing is indicated for any RGM that is con-
sidered clinically significant (e.g., isolates from blood, tissue,
skin, and soft tissue lesions) (14, 15), and clinical laborato-
ries require standardized methods for determining the antimi-
crobial susceptibilities of RGM. Broth microdilution is con-
venient and widely used for the rapid susceptibility testing
to several antibiotics of large numbers of bacterial isolates.
However, MICs as determined by the broth microdilution
are obtained by taking visual turbidity readings, which makes
the test subjective and variable (15, 17). Moreover, the growth
of RGM in microtiter trays frequently does not result in a
well-defined button in the bottom of a well, as occurs with
rapidly growing aerobic and facultative bacteria. In addition,
when testing clarithromycin susceptibility in broth, some
rapidly growing mycobacteria, particularly M. fortuitum, had
trailing end points with certain drugs. 
Because of variabilities in the appearances of the growths
of M. fortuitum and M. abscessus in microdilution trays, inter-
pretation of MICs may be difficult. To avoid these drawbacks,
the colorimetric redox indicator STC was used in the broth
microdilution method in the present study. Results could
be read visually or by spectrophotometry, and the use of a
tetrazolium compound as an indicator made reading straight-
forward because of the obvious color change (19, 20), which
overcomes the problems frequently encountered in the con-
ventional broth microdilution test, such as, inoculum sedi-
mentation or scant or transparent growth (20, 29). Several
attempts have been made to use colorimetric determinations
of broth microdilution endpoints. These methods are attrac-
tive in that they generate clear-cut endpoints based on visu-
al color changes. STC is an oxidation-reduction indicator
which, in the presence of growing organisms, changes from
colorless to pink. Furthermore, it has been used to test the
susceptibilities of M. tuberculosis to antimycobacterial drugs
(18, 19). Moreover, it has been shown to have some benefits
when compared with other colorimetric redox indicators,
such as 3-(4,5-dimethyl-2-thiazy)-2,5-diphenyl-2H-tetra-
zolium bromide (MTT) or 2,3-bis (2-methoxy-4-nitro-5-sul-
fophenyl)-5-[(phenyl-amino) carbonyl]-2H-tetrazolium hy-
droxide (XTT) (30, 31). However, the use of these tetrazoli-
um derivatives has several drawbacks. In MTT assays, a large
number of cells are necessary (32), and XTT is expensive for
routine use in clinical laboratories. Additionally for MTT and
XTT methods, substrate should be added after growth has
begun, and the time of this addition is not well defined (33),
and in our experience the developed color disappears within
Species 
(No.of 
strains)
M. fortuitum (55)
Minor* Major*
Very
major*
Agents
M. abscessus (48)
Minor* Major*
Very
major*
Amikacin 0 0 0 0 0 0
Cefoxitin 15 0 0 2 0 0
Ciprofloxacin 2 0 0 19 0 1
Clarithromycin 1 0 0 4 0 0
Doxycycline 3 0 0 5 0 0
Imipenem 1 0 0 0 1 0
Sulfamethoxazole - 5 0 - 0 8
Table 5. Agreement by interpretative category among CLSI and
STC broth microdilution methods 
*Very major error, resistant by the CLSI method but susceptible by the
STC method; major error, susceptible by the CLSI method but resistant
by the STC method; minor error, intermediate result was obtained by
one method but not by the other.Broth Microdilution Method Using STC for RGM 789
a day. In the modified susceptibility testing method using
STC, the substrate can be added to media at the time of
preparing media before inoculating bacteria. The plate agi-
tation process can be eliminated, which is necessary in the
MTT and XTT methods and may cause reading errors. In
the present study, an excellent correlation was obtained bet-
ween the results of the CLSI and STC methods. Especially
the MIC and interpretive category results obtained from
sulfamethoxazole susceptibility tests showed some discrep-
ancies. We consider that the lack of an intermediate catego-
ry of interpretation criteria causes major or very major errors
even for a 2-fold dilution MIC difference. The CLSI guide-
line recommends that MIC results of sulfamethoxazole should
be read at the concentration in which there is 80% or greater
reduction in growth as compared to the control because antag-
onists in the medium may allow some slight growth (15,
28). Actually small growth of organism in microwell could
be skipped in the CLSI broth microdilution method while
more easily detected by color change of media in the STC
method. Thus sulfamethoxazole susceptibility results should
be cautiously interpreted in both broth microdilution methods. 
In this study, we describe the general susceptibility patterns
of M. fortuitum and M. abscessus in Korea. In addition, it was
demonstrated that the STC broth microdilution method is
reliable, easy to perform, and inexpensive for susceptibility
testing of isolates of M. fortuitum and M. abscessus to 7 antimi-
crobial agents. In comparison with the broth microdilution
method approved by CLSI, the colorimetric MIC testing by
the modified broth microdilution method using STC could
provide a useful means for the antibiotic susceptibility test-
ing for RGM.
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